Akebia Q4 net product revenue $54.3M, full-year 2025 up 49% YoY; Vafseo launch gains traction

Akebia Therapeutics, Inc.

2025-FY EPS reported -$0.02 revenue$236,196,000

Q4 total revenue $57.6M (FY2025 $236.2M); net loss narrowed to $12.2M Q4 and $5.3M full year.
Vafseo net product revenue $6.2M Q4, $45.8M full year 2025; 800 prescribers, 91% adherence with observed dosing.
Auryxia net rev $181.5M FY2025; generic competition expected to reduce 2026 Auryxia revenue.
Cash $184.8M vs $51.9M year-end 2024; sufficient for at least two years.
Pipeline: praliciguat Phase 2 FSGS started; AKB-097 basket study in 2H 2026; AKB-9090 Phase 1 in 1H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.